Qiagen receives EUA for portable SARS-CoV-2 antigen test

By LabPulse.com staff writers

August 6, 2021 -- Qiagen announced it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its QIAreach SARS-CoV-2 Antigen Test, a rapid portable test that the company said can analyze over 30 samples per hour for the SARS-CoV-2 antigen.

The company touted its test, developed in collaboration with Ellume, as providing digital results in two to 15 minutes. It also uses Qiagen's Underwriters Laboratories (UL)-certified eHub, a portable reader with backup battery power that can be operated remotely from the main power for up to eight hours.

Qiagen and Sysmex form strategic alliance
Qiagen announced it has entered a strategic alliance with partner Sysmex for the development and commercialization of next-generation sequencing products...
Qiagen, Verogen to offer forensic testing kits, services
Qiagen and Verogen have teamed up to offer labs tools and support for human identification workflows in forensic testing based on next-generation sequencing.
FDA expands use of Qiagen lung cancer mutation test
The U.S. Food and Drug Administration (FDA) approved the expanded use of a Qiagen diagnostic kit as a companion test for the identification of non-small...
Qiagen inks deal with Mirati on cancer companion diagnostic
Qiagen has announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based, KRAS companion diagnostic to identify patients...
Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...

Copyright © 2021 LabPulse.com

Last Updated ls 8/6/2021 2:07:26 PM